THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

FDA proposes draft guidelines on AI use in drug development, addressing challenges and opportunities for improving safety and ...

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the ...

A new Phase I clinical trial from London Health Sciences Centre Research Institute (LHSCRI) has found high-precision radiation therapy is safe for use in patients with cancer that has spread ...

The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.